Department of Cardiovascular, Guang'anmen Hospital, China Academy of Chinese Medical Sciences.
Graduate School, Beijing University of Chinese Medicine, Beijing, China.
Medicine (Baltimore). 2021 Jan 22;100(3):e24434. doi: 10.1097/MD.0000000000024434.
The combination of Chinese patent medicine Wenxin Granules (WXG) and antiarrhythmic drugs has been widely used in the treatment of atrial fibrillation (AF), but the results are controversial. This study will conduct a network meta-analysis (NMA) based on data from randomized controlled trials to evaluate the efficacy and safety of WXG combined with ADDs (amiodarone, metoprolol, propafenone, bisoprolol, or other antiarrhythmic drugs) in the treatment of AF, which will perform comparisons or rankings of efficacy among the currently available therapeutic schemes in order to provide evidence to determine the optimal threshold and treatment regimen to AF patients.
A comprehensive systematic literature search will be conducted in Cochrane Library, PubMed, Web of Science, EMBASE, Chinese Biomedical Literature Database (SinoMed), Chinese National Knowledge Infrastructure (CNKI), and WanFang database for randomized controlled trials about the WXG with ADDs. The NMA will be conducted following the PRISMA-NMA guidelines. Statistical analyses will be conducted by using Stata software (version 14.0) and RevMan software (version 5.3).
The results of this NMA will provide a high-quality evidence for the efficacy of WXG combined with ADDs in the treatment of AF, and a ranking of the therapeutic classes will also be presented.
The protocol will provide updated evidence for the application of WXG for AF.
中药稳心颗粒(WXG)与抗心律失常药物联合应用于心房颤动(AF)的治疗已较为广泛,但疗效尚存争议。本研究将基于随机对照试验的数据进行网状 Meta 分析(NMA),以评估 WXG 联合 ADD(胺碘酮、美托洛尔、普罗帕酮、比索洛尔或其他抗心律失常药物)治疗 AF 的疗效和安全性,对现有治疗方案的疗效进行比较或排序,旨在为确定 AF 患者的最佳阈值和治疗方案提供证据。
我们将全面检索 Cochrane Library、PubMed、Web of Science、EMBASE、中国生物医学文献数据库(SinoMed)、中国知网(CNKI)和万方数据库中关于 WXG 联合 ADD 治疗 AF 的随机对照试验。本研究将遵循 PRISMA-NMA 指南进行 NMA。采用 Stata 软件(版本 14.0)和 RevMan 软件(版本 5.3)进行统计分析。
本 NMA 的结果将为 WXG 联合 ADDs 治疗 AF 的疗效提供高质量证据,并对治疗类别进行排序。
本方案将为 WXG 在 AF 中的应用提供最新证据。